Lipella Pharmaceuticals Inc. (LIPO) Income Statement
LIPO 2024 at a glance
Fiscal year ended December 31, 2024 · U.S. dollarsLIPO revenue and net income
Where LIPO's revenue goes
2024Each bar shows an amount and its share of revenue. LIPO kept −935.2% of revenue as net income.
LIPO profit margins
LIPO growth rates
to 2024| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +19.3% | +27.4% | −5.0% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LIPO quarterly EPS vs estimates
Lipella Pharmaceuticals beat the analyst EPS estimate in 2 of the last 5 quarters.
LIPO income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue | $536,357 | $449,617 | $184,156 | $259,347 | $961,683 | $694,748 |
| Cost of revenue | $3.6M | $3.0M | $2.5M | $1.5M | $975,960 | $682,891 |
| Gross profit | −$3.1M | −$2.6M | −$2.4M | −$1.2M | −$14,277 | $11,857 |
| Research & development | $3.6M | $3.0M | $2.5M | $1.5M | $975,960 | $682,891 |
| Sales, general & admin | $2.0M | $2.2M | $226,192 | $718,384 | $42,585 | $65,648 |
| Total operating expenses | $2.0M | $2.2M | $226,192 | $718,384 | $42,585 | $65,648 |
| Operating income | −$5.1M | −$4.7M | −$2.6M | −$1.9M | −$56,862 | −$53,791 |
| Interest income | $64,278 | $97,168 | $1,678 | $104 | $3,171 | — |
| Interest expense | $0 | $10,848 | $9,612 | $6,834 | $7,965 | $8,391 |
| Income before taxes | −$5.0M | −$4.6M | −$2.6M | −$1.9M | −$61,656 | −$61,848 |
| Income taxes | −$5.02B | $5 | −$1,633 | $6,730 | $4,794 | −$53,791 |
| Net income | −$5.0M | −$4.6M | −$2.6M | −$1.9M | −$61,656 | −$61,848 |
| EBITDA | −$5.0M | −$4.6M | −$2.6M | −$1.9M | −$53,691 | $334 |
| EPS (diluted) | −$3.60 | −$4.97 | −$0.55 | −$3.85 | −$0.06 | — |
| Gross margin | −573.7% | −575.9% | −1,283.4% | −461.7% | −1.5% | 1.7% |
| Operating margin | −947.2% | −1,055.6% | −1,406.3% | −738.7% | −5.9% | −7.7% |
| Net margin | −935.2% | −1,027.3% | −1,410.6% | −719.3% | −6.4% | −8.9% |
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $86.7M | $129.4M | $173,666 | $80,380 | $136,431 | $145,880 | $449,617 | $104,051 | $106,676 | $118,048 | $151,007 |
| Cost of revenue | $720,973 | $791,581 | $993,475 | $1.1M | $1.0M | $661,558 | $842,600 | $454,200 | $833,260 | $1.1M | $693,730 | $478,103 |
| Gross profit | −$720,973 | −$791,581 | −$993,475 | −$888,670 | −$1.0M | −$661,558 | −$842,600 | −$4,583 | −$729,209 | −$1.1M | −$693,730 | −$327,096 |
| Research & development | $721.0M | $791.6M | $993.5M | $1.1M | $1.0M | $661,558 | $842,600 | $454,200 | $833,260 | $1.1M | $693,730 | $478,103 |
| Sales, general & admin | $553,299 | $651,721 | $463,736 | $562,622 | $493,102 | $427,062 | $520,926 | $396,236 | $627,518 | $624,231 | $508,750 | $32,167 |
| Total operating expenses | $553,299 | $564,994 | $334,346 | $562,622 | $412,722 | $290,631 | $375,046 | $725,011 | $627,518 | $517,555 | $390,702 | $32,166 |
| Operating income | −$1.3M | −$1.4M | −$1.3M | −$1.5M | −$1.5M | −$952,189 | −$1.2M | −$729,594 | −$1.4M | −$1.6M | −$1.1M | −$359,262 |
| Interest income | $20,194 | $29,089 | $21,298 | $9,620 | $14,778 | $14,043 | $25,837 | $40,710 | $33,157 | $41,968 | $22,001 | $42 |
| Interest expense | — | — | — | $0 | $0 | $0 | $0 | $10.9M | $0 | $5,454 | $5,394 | $4,704 |
| Income before taxes | −$1.3M | −$1.3M | −$1.3M | −$1.4M | −$1.4M | −$938,146 | −$1.2M | −$688,884 | −$1.3M | −$1.5M | −$1.1M | −$363,925 |
| Income taxes | — | — | — | — | — | −$1,371 | −$2 | −$58.4M | $33.1M | $36.5M | −$11.2M | −$1,131 |
| Net income | −$1.3M | −$1.3M | −$1.3M | −$1.4M | −$1.4M | −$938,146 | −$1.2M | −$688,884 | −$1.3M | −$1.5M | −$1.1M | −$363,925 |
| EBITDA | −$1.3M | −$1.3M | −$1.3M | −$1.4M | −$1.4M | −$936,775 | −$1.2M | −$688,161 | −$1.3M | −$1.5M | −$1.1M | −$359,221 |
| EPS (diluted) | −$0.28 | −$0.31 | −$0.64 | −$1.19 | −$1.29 | −$0.96 | −$0.16 | −$0.80 | −$1.84 | −$2.14 | −$0.19 | −$0.09 |
| Gross margin | — | −0.9% | −0.8% | −511.7% | −1,302.2% | −484.9% | −577.6% | −1.0% | −700.8% | −991.5% | −587.7% | −216.6% |
| Operating margin | — | −1.6% | −1.0% | −835.7% | −1,815.6% | −697.9% | −834.7% | −162.3% | −1,303.9% | −1,476.6% | −918.6% | −237.9% |
| Net margin | — | −1.5% | −1.0% | −830.1% | −1,797.3% | −687.6% | −817.0% | −153.2% | −1,272.0% | −1,442.4% | −904.6% | −241.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LIPO's financial statements (latest annual report filed March 28, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LIPO financial results
In fiscal year 2024 (ended December 31, 2024), Lipella Pharmaceuticals reported revenue of $0.5 million, up 19.3% from the year before. It had a net loss of $5.0 million, a net profit margin of −935.2%. Diluted earnings per share came to −$3.60. Over five years revenue grew at an average rate of −5.0% a year.
See the LIPO stock overview for the latest quote and news, or the LIPO chart for price history and technical indicators.
LIPO income statement FAQ
What is Lipella Pharmaceuticals's annual revenue?
Lipella Pharmaceuticals reported total revenue of $0.5 million for fiscal year 2024, which ended on December 31, 2024. That was up 19.3% from $0.4 million the previous year.
Is Lipella Pharmaceuticals profitable?
No. Lipella Pharmaceuticals reported a net loss of $5.0 million in fiscal 2024, a net profit margin of −935.2%; its operating margin was −947.2%.
What is Lipella Pharmaceuticals's gross margin?
Lipella Pharmaceuticals's gross margin was −573.7% in fiscal 2024: for every $100 of revenue, Lipella Pharmaceuticals kept $-574 after the direct cost of its products and services.
How much does Lipella Pharmaceuticals spend on research and development?
Lipella Pharmaceuticals spent $3.6 million on research and development in fiscal 2024, 673.7% of revenue.
How fast is Lipella Pharmaceuticals growing?
Revenue grew −5.0% a year on average over the last five fiscal years, from $0.7 million to $0.5 million.
What are Lipella Pharmaceuticals's earnings per share?
Lipella Pharmaceuticals earned $-3.60 per diluted share in fiscal 2024, compared with $-4.97 a year earlier.
When does Lipella Pharmaceuticals's fiscal year end?
Lipella Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2024 and was filed on March 28, 2025.